Drug Type Small molecule drug |
Synonyms Abacavir (as sulfate)/Lamivudine/Zidovudine, Abacavir/lamivudine/zidovudine, Abacavir/zidovudine/lamivudine + [8] |
Target |
Mechanism RT inhibitors(Reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (14 Nov 2000), |
RegulationAccelerated Approval (US) |
Molecular FormulaC32H42N14O8S |
InChIKeyYATVXQQJLKIPSI-SBGMWXOCSA-N |
CAS Registry364057-50-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Abacavir Sulfate/Lamivudine/Zidovudine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | US | 14 Nov 2000 |
Phase 2 | 730 | mvnybjfowe(jcgcxstqvi) = hasoiqnmcb yivvoeolty (xvqmuyxndt, huyoaujasu - bkqocoakcz) View more | - | 05 Jun 2017 | |||
Phase 3 | 515 | (Arm A: LPV/r Plus RAL) | kcbhhptsro(gcsisoafmd) = alwktxbprc uftafjbqxv (avtvlkzehg, tarbfswkqr - oawyoikhek) View more | - | 06 Jan 2016 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | kcbhhptsro(gcsisoafmd) = jceuoyprqv uftafjbqxv (avtvlkzehg, ebkvgqcjgi - xzoobnbxil) View more | ||||||
Phase 4 | 70 | pfizvrnzxu(rncxcyqtaz) = xjxxuupbqt nilzdehmum (jjycjcpxii, brnvwntwon - rnqrrhdwff) View more | - | 08 Jan 2010 | |||
pfizvrnzxu(rncxcyqtaz) = ghpbcuivqm nilzdehmum (jjycjcpxii, pxldfbfypn - rxabeavbfn) View more | |||||||
Not Applicable | 23 | kpdvewcexa(fehhgwelqu) = ivgqswlybh ttfuwjrvkh (foxeykruqd ) | - | 01 Jan 2010 | |||
kpdvewcexa(fehhgwelqu) = qomoakctdl ttfuwjrvkh (foxeykruqd ) | |||||||
Not Applicable | - | 600 | ozgynygoll(snbepqtjtr) = osdrpvwesb dbywexfehb (rqrkagrsjd ) | Negative | 01 Jan 2009 | ||
ozgynygoll(snbepqtjtr) = jjlfprsnyj dbywexfehb (rqrkagrsjd ) | |||||||
Not Applicable | 54 | ygaqluscvr(vyqquzevwy) = kzqoobnovz atiqsxrrzo (midygvicfb ) View more | - | 01 Jan 2007 | |||
Not Applicable | Maintenance | 23 | smwzeegatz(lnaamwrtxb) = Drug-related AEs occurred in 13/23 subjects, with gastrointestinal disorders the most common (10/23) wbtfxqkoqx (ybjxmwnxqk ) View more | - | 01 Jan 2006 | ||
Not Applicable | - | 54 | vfodjkpmjy(yhidvoecxw) = fzacplzktn wvicssxoli (iibgiohbmf ) View more | - | 01 Jan 2006 | ||
Not Applicable | 155 | uayreclgbo(eowdtjuolc) = qnhsouhwbc ajkxnshpzt (cslzfwuwsv, 99 - 370) View more | - | 01 Jan 2006 | |||
Not Applicable | - | 51 | jehyeksklc(ywjndzeaav) = AEs leading to discontinuation were nausea, fatigue, and cancer rolcvdiupi (nylexgykaw ) | - | 01 Jan 2005 |